Affiliation:
1. Federal Center of Toxicological, Radiation and Biological Safety
Abstract
No radiation protection agents have been found to date which would not have toxic side effects while having radioprotective action of unlimited duration. Based on the screening of organo-element chemical compounds, a novel radioprotector sulfotozifan was selected to prevent the acute radiation syndrome in animals. Sulfotozifan belongs to compounds of hazard class 3 (National Standard of the Russian Federation (GOST) 12.1:007.76). A single subcutaneous administration of sulfotozifan at a dose of 38.0 mg / kg of body weight 2-4 days prior to the radiation exposure of animals to an absolute lethal dose, protects 80-100% of the animals from the radiation death. The pretreatment of animals with sulfotozifan 2-4 days prior to the irradiation has a positive effect on the animals’ clinical condition, normalizes their hematological parameters, increases the levels of T and B lymphocytes, inhibits peroxidation of lipids (POL), reduces the concentration of malondialdehyde (MDA), the final product of POL, in the erythrocyte hemolysate and blood plasma, and also promotes a reduction in the formation of radiotoxins. By its organoleptic, physicochemical, and bacterioscopic characteristics, the meat from irradiated animals pretreated with sulfotozifan does not differ significantly from those of the meat from the control animals and thus meets GOST requirements.
Publisher
Trans Tech Publications, Ltd.
Subject
Mechanical Engineering,Mechanics of Materials,General Materials Science
Reference9 articles.
1. T.E. Tkachenko, Relationship between biochemical parameters of blood and dairy productivity of cows, Zootechniya 4 (2003) 17–20 (in Russian).
2. A.P. Surzhikov, T.S. Frangulyan, S.A. Ghyngazov, E.N. Lisenko, O.V. Galtseva, Physics of magnetic phenomena: Investigation of electroconductivity of lithium pentaferrite, Russian Physics Journal 49(5) (2006) 506-510.
3. T.R. Mosrnann, Two types of murine helper T cell clone. J. Definition according to profiles of lymphokine activities and secreted proteins, Immunology 136 (2006) 2348-2357.
4. T.A. Waldmann, Immunotherapy: past, present and future, Nat Med 9(3) (2003) 269–277.
5. C. Termeer, J. Hennies, U. Voith, Th. Ahrens, J.M. Weiss, P. Prehm, J.C. Simon, Oligosaccharides of Hyaluronan Are Potent Activators of Dendritic Cells, J Immunol 165(4) (2011) 1863–1870.